Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.
Coordinate fetal-maturation treatment, magnesium neuroprotection and safe in-utero transfer according to gestation, likelihood of birth and maternal or fetal stability.
Preterm optimisation is a coordinated treatment package rather than a race to tick off medicines. Corticosteroids accelerate fetal maturation and reduce important neonatal complications. Magnesium sulfate, given close to an imminent early birth, reduces neurological risk. In-utero transfer places the mother and infant where the needed neonatal care is available before delivery. These interventions address different problems and have different timing rules. The first question remains whether continued pregnancy and transfer are safe; treatment should support the clinical plan, not dictate an unsafe delay.
Steroid decisions depend on gestation, anticipated interval to birth, previous exposure and maternal circumstances. NICE recommends discussion at 22+0–23+6 weeks, offering treatment at 24+0–33+6 and considering it at 34+0–35+6. RCOG Green-top 74 recommends offering through 34+6 weeks, reflecting its assessment of the evidence, with careful benefit-harm consideration beyond this. Explain this source distinction when choosing the service pathway. At extreme prematurity, neonatal counselling and the agreed approach to the infant's care are part of the decision. Avoid administering courses merely because a pregnancy is statistically high risk when imminent delivery is unlikely.
Established labour, planned medically indicated early birth or a convincing threatened-labour assessment identifies when optimisation may have a realistic benefit.
Pre-existing or gestational diabetes requires an anticipatory glucose plan before steroids, rather than reacting only after substantial hyperglycaemia develops.
Oliguria, renal dysfunction, depressed reflexes or slowing respiration signals a need to review exposure and stop or reduce treatment promptly.
Advanced labour, uncontrolled haemorrhage, maternal instability or fetal deterioration may make delivery and neonatal preparation locally the safer option.
Use for fetal maturation is off label in relevant UK preparations; check diabetes management, prior courses and the risk of neonatal hypoglycaemia after late-preterm exposure.
Confirm the injectable formulation and prescribed course, do not mix partial regimens without a documented specialist decision, and count previous fetal-maturation courses.
Neuroprotection is an off-label indication. Renal failure, oliguria, respiratory depression or loss of tendon reflexes requires urgent reassessment and dose reduction or cessation.
Steroids seek a useful maturation interval, magnesium targets imminent birth, and transfer should occur before the patient becomes too unstable or advanced in labour.
A second course needs specific eligibility below 34 weeks; serial weekly courses are not an acceptable response to persistent uncertainty about delivery.
An early dose can be worthwhile when time is short, but its potential benefit never justifies delaying a birth required for maternal or fetal survival.
At extreme prematurity the receiving centre should understand the family's discussion and agreed care approach, with opportunities to revisit decisions as circumstances evolve.
Delaying necessary emergency birth to finish the second corticosteroid injection.
Leaving magnesium running beyond the intended stop point because transfer or delivery timing has changed.
Giving a second magnesium loading dose at the receiving unit without checking the sending unit's medication record.
Quoting the old 2019 extreme-prematurity information as current when the BAPM 2026 framework provides revised counselling guidance and outcome data.
Your practice draft is saved in this browser.
A patient at 27+5 weeks is in established labour, has normal renal function and has agreed active neonatal care. Which magnesium sulfate neuroprotection regimen matches NICE recommendations?
National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 7 Sept 2026; clinical approval remains outstanding.
Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes
Magnesium neuroprotection is not routine maintenance tocolysis and is not prescribed throughout a long period of threatened labour. NICE ties eligibility to established labour or a planned birth within 24 hours. A renal impairment or low urine output raises toxicity risk because magnesium clearance falls. Observe breathing, reflexes and haemodynamics and ensure immediate access to resuscitation and the local magnesium-toxicity treatment pathway. Prolonged or repeated exposure needs particular attention to total dose and neonatal calcium, magnesium and skeletal effects.
In-utero transfer is usually preferable to transferring an unstable very preterm infant after birth, but only if the mother's condition and stage of labour permit the journey. Contact receiving obstetric and neonatal teams and the transport service early. Confirm both maternity acceptance and the relevant neonatal capacity, communicate the agreed resuscitation approach and provide a clear handover of membranes, infection risk, bleeding, cervical change and medicines. Reassess immediately before departure; a patient can progress from transferable to unsafe-to-transfer while arrangements are made.